金山科研平台，产品价格货期咨询微信：jinshanbio Source:Mouse myeloma cell line, NS0-derived Accession #:Q60607 N-terminal Sequence Analysis:No results obtained: Gln24 predicted Structure:Disulfide-linked homodimer Purity:>95%, by SDS-PAGE under reducing conditions and visualized by silver stain. Endotoxin Level: Predicted Molecular Mass:41.5 kDa (monomer) SDS-PAGE:55 kDa, reducing conditions Activity:Measured by its ability to inhibit rhBMP-4-induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells. Nakamura, K. et al. (1999) Exp. Cell Res. 250:351.The ED₅₀ for this effect is typically 0.05 - 0.2 µg/mL in the presence of 30 ng/mL of recombinant human BMP-4. Molecule Information: BMPR-IA/ALK-3 Long Name: Bone Morphogenetic Protein Receptor IA/Activin Receptor-like Kinase 3 Aliases: ALK-3; BMPR1A; CD292 Entrez Gene IDs: 657 (Human); 12166 (Mouse) Background: BMP Receptors Cellular responses to bone morphogenetic proteins (BMPs) are mediated by the formation of hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. There are seven known type I serine/threonine kinases and five mammalian type II serine/threonine kinase receptors that function in TGF-beta superfamily signal transduction. The type II receptors for TGF-beta and activin bind ligands with high affinity by themselves. In contrast, BMPR-II binding to BMP-2, BMP-4, and BMP-7 is facilitated by the presence of the type I receptor. The type I receptors are also known as activin receptor-like kinases or ALKs.